Conolidine’s analgesic consequences stem from its conversation with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors from the central anxious method, conolidine modulates alternate molecular targets. A Science Developments review observed that conolidine interacts Along with the atypical chemokine receptor ACKR3/CXCR7